Mostrar el registro sencillo del ítem
| dc.contributor.author | Ruiz-Lorente, Inmaculada | |
| dc.contributor.author | Vallejo-Pulido, Andres | |
| dc.contributor.author | López-Abad, Alicia | |
| dc.contributor.author | López-Cubillana, Pedro | |
| dc.contributor.author | Barozi, Victor | |
| dc.contributor.author | Khakoo, Salim-I. | |
| dc.contributor.author | Minguela-Puras, Alfredo | |
| dc.contributor.author | Gimeno-Arias, Lourdes | |
| dc.date.accessioned | 2026-11-18T11:23:21Z | |
| dc.date.available | 2026-11-18T11:23:21Z | |
| dc.date.issued | 2026-12-31 | |
| dc.identifier.citation | Ruiz-Lorente I, Vallejo-Pulido A, López-Abad A, López Cubillana P, Barozi V, Khakoo SI, et al. Cancer patient outcomes correlate with activating-KIR | |
| dc.identifier.issn | 2162-402X | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/29302 | |
| dc.description.abstract | BACKGROUND: Rates of cancer cure increase; however, recurrence and refractoriness remain clinical challenges that require alternative therapeutic strategies. Natural killer (NK) cells could play a decisive role if their antitumor reactivity can be enhanced. The interaction between killer-cell immunoglobulin-like receptors (KIRs) and their human leukocyte antigen class-I (HLA-I) ligands significantly influences NK-cell education and may impact clinical outcomes in cancer patients. In this study, we evaluated the impact of KIR/HLA-I interactions on the transcriptomic profile of circulating NK-cells and their association with patient outcome. METHODS: KIR and HLA-I genotyping, together with KIR expression analysis in circulating NK cells, were performed in patients with solid and hematologic malignancies (n = 1,153). In addition, single-cell transcriptomic analyses (scRNA-seq) of circulating NK and T lymphocytes were carried out in selected donors with KIR/HLA-I genotypes associated with short and long survival. RESULTS: Activating KIRs (aKIRs), more than inhibitory KIRs, were associated with cancer patient outcomes. The accumulation of aKIR-HLA interactions was related to shorter overall survival, whereas KIR2DS1/C2 interaction, in the absence of other aKIR interactions, was associated with longer survival. Three major NK-cell transcriptional profiles were identified: mature cytotoxic, immature/regulatory, and adaptive cytotoxic. The adaptive-like transcriptional profile was associated with longer survival. CONCLUSIONS: In conclusion, aKIR/HLA-I interactions were associated with cancer patient outcomes. In particular, KIR2DS1/C2 interaction in the absence of other activating signals was associated with adaptive NK-cell transcriptomic profiles and improved survival. Understanding the mechanisms underlying effective NK-cell-mediated tumor immunity may provide new opportunities for patients with refractory tumors. | |
| dc.language.iso | eng | |
| dc.publisher | TAYLOR & FRANCIS INC | |
| dc.rights | Atribución/Reconocimiento-NoComercial 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/deed.es | * |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Killer Cells, Natural/immunology/metabolism | |
| dc.subject.mesh | Receptors, KIR/genetics/metabolism | |
| dc.subject.mesh | Transcriptome | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Neoplasms/genetics/immunology/mortality | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Ligands | |
| dc.subject.mesh | Gene Expression Profiling | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Genotype | |
| dc.subject.mesh | Histocompatibility Antigens Class I/genetics/metabolism | |
| dc.subject.mesh | Prognosis | |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Aged | |
| dc.title | Cancer patient outcomes correlate with activating-KIR/ligand repertoires associated with distinct NK cell transcriptomic profiles | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 42980150 | |
| dc.relation.publisherversion | https://www.tandfonline.com/doi/full/10.1080/2162402X.2026.2756722 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1080/2162402X.2026.2756722 | |
| dc.journal.title | ONCOIMMUNOLOGY |